Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.

@article{Grohar2011Ecteinascidin7I,
  title={Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.},
  author={P. Grohar and L. Griffin and C. Yeung and Q. Chen and Y. Pommier and C. Khanna and J. Khan and L. Helman},
  journal={Neoplasia},
  year={2011},
  volume={13 2},
  pages={
          145-53
        }
}
ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor. In this report, we show that modulation of specific oncogenic transcription factors by ET-743 may extend to other tumor types. We demonstrate that, among a panel of pediatric sarcomas, Ewing sarcoma family of tumors (ESFTs) cell lines bearing… Expand
Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner
Phosphoproteomic Profiling Reveals IL6-Mediated Paracrine Signaling within the Ewing Sarcoma Family of Tumors
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naïve patients
The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors.
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
ET-743: a novel agent with activity in soft-tissue sarcomas
Ecteinascidin-743 inhibits activated but not constitutive transcription.
A Molecular Function Map of Ewing's Sarcoma
Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma
...
1
2
3
4
5
...